Peptide
Triptorelin (Trelstar)
Triptorelin is a synthetic decapeptide GnRH agonist. FDA-approved in 2000, available as 1-month (3.75mg), 3-month (11.25mg), and 6-month (22.5mg) formulations. Clinical trials show 97.5% achieve castrate testosterone by day 29 with 6-month formulation. 9-month survival significantly higher than leuprolide (97.0% vs 90.5%, p=0.033). Also approved for adjuvant breast cancer treatment.
- Updated
- How we grade
- 42 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade A
- Conditions studied
- 2
- Outcomes
- 10
- Graded outcomes
- 6211
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
Key findings
- Overall SurvivalImproves (the measure goes up)
- Disease-Free Survival (Breast)Improves (the measure goes up)
- Testosterone SuppressionImproves (the measure goes down)
Studies cited
42 studies from PubMed
- Efficacy of Triptorelin Combined with Recombinant Human Growth Hormone (rhGH) on Serum Sex Hormones, Bone Age, and Clinical Outcomes in Girls with Precocious Puberty.
- Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies
- PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancer
- GnRH analogue triptorelin acetate induces ovulation in jennies during oestrus.
- A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
- Triptorelin nanoparticle-loaded microneedles for use in assisted reproductive technology.
- The efficacy and safety of triptorelin-therapy following conservative surgery for deep infiltrating endometriosis: A multicenter, prospective, non-interventional study in China.
- Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial.
- Single injection of triptorelin or buserelin acetate in saline solution induces ovulation in mares the same as a single injection of hCG.
- Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
- Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
- Three cases of transient hyperthyroidism after triptorelin treatment - case report and literature review.
- Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer
- Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer
- Long-term effects of GnRH agonists on fertility and behaviour.
- Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation .
- An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
- Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
- Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
- A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
- Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial
- Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors: Hopeful Though Modest Long-term Results.
- Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.
- Pituitary apoplexy induced by triptorelin in patient with prostate cancer.
- Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.
- [Role of GnRH agonists in preserving female fertility].
- Suppression of fertility in pre-pubertal dogs and cats.
- Hormone therapy in premenopausal women with early-stage breast cancer.
- An analytical strategy to characterize the pharmacokinetics and pharmacodynamics of triptorelin in rats based on simultaneous LC-MS/MS analysis of triptorelin and endogenous testosterone in rat plasma.
- Clinical use of deslorelin (GnRH agonist) in companion animals: a review.
- Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer
- Triptorelin in the management of prostate cancer.
- It's all in the timing: ovulation induction in the mare.
- Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial
- Reproductive endocrinology: triptorelin ovarian suppression during breast cancer chemotherapy.
- Triptorelin embonate: a 6-month formulation for prostate cancer.
- Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study
- Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
- [Clinical trial on the effectiveness and safety of triptorelin in treatment of uterine leiomyoma].
- Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer
- Triptorelin approved for prostate cancer treatment.
- Triptorelin acetate administration in early pregnancy: case reports and review of the literature.